Bladder cancer
Rag-01-01
A phase I, single-arm, open label, multicenter, first-in-human trail to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with non-muscle invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guerin (BCG) therapy.
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Bladder cancer
Study Phase
I
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)